AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) is 28.23% higher on its value in year-to-date trading and has touched a low of $1.00 and a high of $2.94 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACRX stock was last observed hovering at around $1.70 in the last trading session, with the day’s loss setting it -0.11% off its average median price target of $5.50 for the next 12 months. It is also 82.33% off the consensus price target high of $9.00 offered by 4 analysts, but current levels are -91.57% lower than the price target low of $0.83 for the same period.
Currently trading at $1.59, the stock is -12.54% and -22.28% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.2 million and changing -6.47% at the moment leaves the stock 1.58% off its SMA200. ACRX registered 47.22% gain for a year compared to 6-month gain of 17.78%. The firm has a 50-day simple moving average (SMA 50) of $1.8948 and a 200-day simple moving average (SMA200) of $1.7377.
The stock witnessed a -6.47% loss in the last 1 month and extending the period to 3 months gives it a 28.23%, and is -4.79% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.77% over the week and 9.31% over the month.
AcelRx Pharmaceuticals Inc. (ACRX) has around 54 employees, a market worth around $189.11M and $5.40M in sales. Fwd P/E is 44.17. Distance from 52-week low is 59.00% and -45.92% from its 52-week high. The company has generated returns on investments over the last 12 months (120.80%).
AcelRx Pharmaceuticals Inc. (ACRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for AcelRx Pharmaceuticals Inc. (ACRX) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 2.20, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
AcelRx Pharmaceuticals Inc. is expected to release its quarterly report on 08/04/2021 and quarterly earnings per share for the current quarter are estimated at -$0.08 with sales reaching $990k over the same period.The EPS is expected to grow by 29.60% this year, but quarterly earnings will post 167.70% year-over-year. Quarterly sales are estimated to grow 156.50% in year-over-year returns.
AcelRx Pharmaceuticals Inc. (ACRX) Top Institutional Holders
108 institutions hold shares in AcelRx Pharmaceuticals Inc. (ACRX), with 2.43M shares held by insiders accounting for 2.04% while institutional investors hold 25.22% of the company’s shares. The shares outstanding are 118.95M, and float is at 116.59M with Short Float at 6.94%. Institutions hold 24.71% of the Float.
The top institutional shareholder in the company is Blackrock Inc. with over 5.64 million shares valued at $6.99 million. The investor’s holdings represent 4.74% of the ACRX Shares outstanding. As of Dec 30, 2020, the second largest holder is Vanguard Group, Inc. (The) with 3.98 million shares valued at $4.93 million to account for 3.34% of the shares outstanding. The other top investors are Rock Springs Capital Management, LP which holds 3.78 million shares representing 3.18% and valued at over $4.69 million, while Morgan Stanley holds 1.59% of the shares totaling 1.9 million with a market value of $2.35 million.
AcelRx Pharmaceuticals Inc. (ACRX) Insider Activity
A total of 13 insider transactions have happened at AcelRx Pharmaceuticals Inc. (ACRX) in the last six months, with sales accounting for 8 and purchases happening 5 times. The most recent transaction is an insider purchase by Angotti Vincent J. ,the company’sChief Executive Officer. SEC filings show that Angotti Vincent J. bought 7,547 shares of the company’s common stock on Jun 15 at a price of $1.33 per share for a total of $10035.0. Following the purchase, the insider now owns 0.47 million shares.
AcelRx Pharmaceuticals Inc. (ACRX): Who are the competitors?
The company’s main competitors (and peers) include Recro Pharma Inc. (REPH) that is trading -58.46% down over the past 12 months and DURECT Corporation (DRRX) that is 35.66% higher over the same period. Cara Therapeutics Inc. (CARA) is 87.56% up on the 1-year trading charts. Short interest in the company’s stock has risen 3.46% from the last report on Feb 11, 2021 to stand at a total of 7.81 million short shares sold with a short interest ratio of 2.13.